

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
02 June 2022 (02.06.2022)



(10) International Publication Number
WO 2022/112526 A1

(51) International Patent Classification:

G01N 33/569 (2006.01) C12Q 1/04 (2006.01)
C12Q 1/70 (2006.01) C12Q 1/689 (2018.01)

(21) International Application Number:

PCT/EP2021/083235

(22) International Filing Date:

26 November 2021 (26.11.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

20383030.2 26 November 2020 (26.11.2020) EP

(71) Applicant: **4D PHARMA LEON, S.L.U.** [ES/ES]; Parque Tecnológico de Leon, Parcela M-10.4, Armunia, 24009 Leon (ES).

(72) Inventors: **CARITE, Christophe Rene Leonard**; c/o 4D Pharma PLC, 5th Floor, 9 Bond Court, Leeds, LS1 2JZ (GB). **MEDARDE, Antonio Fernández**; c/o 4D Pharma PLC, 5th Floor, 9 Bond Court, Leeds, LS1 2JZ (GB).

(74) Agent: **MARSHALL, Cameron John** et al.; Carpmmaels & Ransford LLP, One Southampton Row, London, WC1B 5HA (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to the identity of the inventor (Rule 4.17(i))
- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))
- with (an) indication(s) in relation to deposited biological material furnished under Rule 13bis separately from the description (Rules 13bis.4(d)(i) and 48.2(a)(viii))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: PROCESS

(57) Abstract: The present invention relates to a process for analysing a composition comprising therapeutic bacteria, wherein the process comprises the steps of (a) culturing the composition under conditions which selectively inhibit the growth of the therapeutic bacteria, and (b) analysing the cultured composition of step (a) to determine whether an unwanted organism was present in the composition. The invention also relates to bacteriophage suitable for use in inhibiting the growth of therapeutic bacteria.

WO 2022/112526 A1